Developing a broad and differentiated portfolio of drug candidates to address unmet needs within and beyond psychiatry
Our psychiatric pipeline features a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment alternative for depression, and ultimately, to address a broad range of unmet needs
|Program||Indication||Phase I||Phase II||Phase II||Phase I||Milestone|
|ELE-Psilo||Depression||Phase I Initiation|
Eleusis is exploring the exciting potential of psychedelics beyond psychiatry - as immunomodulatory and neuroprotective medicines. These and other areas are detailed in Science. Welcome to the clinical evolution of psychedelics.